Updated:
Else Nutrition Holdings Inc.
Else Nutrition Holdings Inc. is a publicly traded food-technology company listed on the TSX Venture Exchange under the ticker BABY. Hamutal Yitzhak formed the...
Else Nutrition Holdings Inc.
Else Nutrition Holdings Inc. is a publicly traded food-technology company listed on the TSX Venture Exchange under the ticker BABY. Hamutal Yitzhak formed the venture in Israel before relocating headquarters to Vancouver, Canada, building on earlier pediatric-nutrition intellectual property developed by co-founders. The wealth origin is corporate—equity raised on public markets—rather than a single-family pool, placing it outside the traditional single-family-office structure despite its concentrated founding leadership. The company designs, clinically tests, and licenses whole-plant baby formulas and toddler nutritional drinks that replace dairy protein and soy with a base of almonds, buckwheat, and tapioca. Asset classes in play are limited to its own formulations, serving as intellectual property that generates both direct-to-consumer revenue and long-term licensing fees from multinational partners. In 2020, the company secured the first FDA no-objection letter for a plant-based infant formula not derived from soy, followed by a rollout across major U.S. pharmacy chains. Geographic footprint spans North America through its U.S. retail partnerships, European distributors, and an emerging foothold in the Asia-Pacific market. As of early 2023, the company employed approximately 30 professionals operating from Vancouver, with R&D roots retained in Israel. While no formal family-office-style vehicle sits alongside it, the firm has structured separate manufacturing agreement streams with independent factory partners in North America and Europe to supply both consumer and clinical channels. In January 2024, Else Nutrition secured a multi-year North American distribution agreement with a major broadline grocery distributor, extending its reach beyond direct retail. Else Nutrition exists at the intersection of a public technology company and a licensing platform—a structure rare in pediatric nutrition, where private equity-owned formula brands dominate. The core differentiator is its regulatory-first model: rather than scaling sales aggressively, it pursues clinical validation at academic medical centers to unlock intellectual property value, behaving more like a biotech royalty holder than a consumer packaged-goods firm.
General information
Firm type
Asset Manager
Location
Region
North America
Country
Canada
City
Vancouver
Corporate office
Vancouver, BC, Canada
Principals
Hamutal Yitzhak
CEO & Co-Founder
Sector focus
Frequently asked questions
How does Else Nutrition generate revenue—consumer sales or licensing?
Else Nutrition operates a hybrid model. It sells directly to consumers online and through retail partners in North America, generating branded product revenue. Increasingly, the company is shifting its emphasis to business-to-business licensing, offering its patented clean-label formulations to global dairy and infant-nutrition manufacturers in exchange for royalties. Manufacturing is outsourced through agreements with third-party facilities in North America and Europe.
What regulatory approvals does Else Nutrition hold, and why do they matter?
Else Nutrition received the second-ever FDA no-objection letter for a plant-based infant formula not derived from soy—a crucial gatekeeper for entry into the U.S. market. This regulatory clearance, obtained in 2020, signals that the formula meets minimum U.S. nutritional standards and unlocks retail distribution channels restricted to approved products. The approval also serves as a template for licensing negotiations with international partners seeking FDA-validated ingredients.
Who leads the scientific and product development work at Else Nutrition?
Product development is led by Michael Azar, Chief Scientific Officer, who brings decades of experience in pediatric nutrition innovation. The R&D operations maintain a facility in Israel, where much of the clinical trial design and formulation work is conducted. Azar's team is responsible for the patented almond-and-buckwheat protein base that differentiates Else from soy- and pea-protein competitors.
Which countries currently distribute Else Nutrition products?
Else Nutrition has established retail distribution channels across the United States, including several major pharmacy and grocery chains, as well as a direct-to-consumer e-commerce platform. The company has also expanded into Canada and certain European markets, with nascent partner discussions underway for distribution in Australia and select Asian markets, including China.
How is Else Nutrition funded—does any single family office back it?
Else Nutrition is publicly traded on the TSX Venture Exchange, funding operations through equity capital raised on public markets rather than through a single-family-office backer. Institutional investors and retail shareholders provide capital, making it a conventional public-company structure despite its concentrated founding team and niche therapeutic focus.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: